Status:
COMPLETED
Prevention of Chest Pain in Chemo-treated Cancer Patients
Lead Sponsor:
Vejle Hospital
Collaborating Sponsors:
Region of Southern Denmark
Conditions:
Solid Carcinoma
5-Fluorouracil Toxicity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment o...
Eligibility Criteria
Inclusion
- Histologically verified cancer
- First-time treatment with 5-FU/Capecitabine
- Expected remaining lifetime \> 6 months
- Informed consent
Exclusion
- Known ischemic heart disease
- Ischemia-suspicious symptoms prior to 5-FU treatment
- Ischemia-suspicious ECG-changes prior to 5-FU treatment
Key Trial Info
Start Date :
April 11 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 7 2024
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT03486340
Start Date
April 11 2018
End Date
June 7 2024
Last Update
July 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departments of Oncology and Medicine, Vejle Hospital
Vejle, Denmark